Early Canadian Real-World Experience with Brolucizumab in Anti-Vascular Endothelial Growth Factor-Experienced Patients with Neovascular Age-Related Macular Degeneration: A Retrospective Chart Review
Michel Giunta,1,2 Louis-Pierre Gauvin Meunier,3 Donald Nixon,4,5 Jeff Steeves,6 Jason Noble7,8 1GOGiunta Ophtalmologie, Sherbrooke, QC, Canada; 2Department of Surgery, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada; 3Institut de l’Œil des Laurentides, Boisbriand, QC, Canada;...
Main Authors: | Giunta M, Gauvin Meunier LP, Nixon D, Steeves J, Noble J |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2022-08-01
|
Series: | Clinical Ophthalmology |
Subjects: | |
Online Access: | https://www.dovepress.com/early-canadian-real-world-experience-with-brolucizumab-in-anti-vascula-peer-reviewed-fulltext-article-OPTH |
Similar Items
-
Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects
by: Justus G. Garweg, et al.
Published: (2023-01-01) -
Real-World Frequency and Management of Ocular Adverse Events in Eyes with Neovascular Age-Related Macular Degeneration Treated with Brolucizumab
by: Ryan Zubricky, et al.
Published: (2023-06-01) -
Real-World Experience with Brolucizumab Compared to Aflibercept in Treatment-Naïve and Therapy-Refractory Patients with Diabetic Macular Edema
by: Anne Rübsam, et al.
Published: (2024-03-01) -
A Real-World, Multicenter, 6-Month Prospective Study in Greece of the Effectiveness and Safety of Ranibizumab in Patients with Age-Related Macular Degeneration Who Have Inadequately Responded to Aflibercept: The “ELEVATE” Study
by: Rouvas A, et al.
Published: (2022-08-01) -
Imaging Features of Retinal Vasculitis and/or Retinal Vascular Occlusion after Brolucizumab Treatment in the Postmarketing Setting
by: Dilraj S. Grewal, MD, et al.
Published: (2024-01-01)